NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel and Company Overview
TL;DR
Tonix Pharmaceuticals appoints experienced General Counsel Irina Ishak to strengthen legal oversight as it commercializes TONMYA and advances its pipeline for competitive advantage.
Tonix Pharmaceuticals appoints Irina Ishak as General Counsel to lead legal, governance, and compliance functions, supporting product commercialization and strategic execution with her corporate experience.
Tonix Pharmaceuticals' appointment of Irina Ishak supports advancing treatments for fibromyalgia and other conditions, potentially improving quality of life for millions of patients.
Tonix Pharmaceuticals' new General Counsel Irina Ishak previously contributed to the development and launch of KRYSTEXXA, bringing valuable experience to the company.
Found this article helpful?
Share it with your network and spread the knowledge!
Tonix Pharmaceuticals Holding Corp. has appointed Irina Ishak as its new General Counsel, effective December 8, 2025.
Irina Ishak is a longtime advisor to Tonix who previously served as Senior Counsel at Lowenstein Sandler LLP, where she advised Tonix on financings, licensing, strategic transactions, commercial agreements, and governance matters. She also previously held senior legal roles at Savient Pharmaceuticals.
She will lead Tonix's legal, corporate governance, and compliance functions.
CEO Seth Lederman stated that her corporate and transactional experience will support Tonix as it commercializes products, advances its pipeline, and executes its long-term strategy during a pivotal period following the launch of its FDA-approved fibromyalgia therapy.
Tonix markets FDA-approved TONMYA™ for fibromyalgia, Zembrace® SymTouch® (sumatriptan injection) for acute migraine, and Tosymra® (sumatriptan nasal spray) for acute migraine.
TONMYA is the first FDA-approved fibromyalgia therapy in more than 15 years and is a first-in-class, non-opioid analgesic medicine.
Tonix's development portfolio focuses on central nervous system disorders, immunology, immuno-oncology, rare disease, and infectious disease.
Key development candidates include TNX-102 SL for acute stress reaction/disorder and major depressive disorder, TNX-1500 for organ transplant rejection and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, TNX-801 for mpox and smallpox, TNX-4800 for Lyme disease prevention, and TNX-4200 for broad-spectrum antiviral applications.
The full press release can be viewed at https://ibn.fm/UH3pO.
Curated from InvestorBrandNetwork (IBN)
